DRL gears up for biosimilar push, consumer health growth post record FY25

May 20, 2025

Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by analysts.

More To Explore

India a top growth market but still underowned globally: Matt Orton

Matt Orton from Raymond James Investment visited India for an investor conference. He finds Indian infrastructure development exciting. Orton is looking deeper into L&T due

June 3, 2025

Bank Nifty crosses 56,000 to hit record high as RBI rate decision looms

The Nifty Bank index crossed the 56,000 mark for the first time on Tuesday, driven by gains in select lenders ahead of an anticipated RBI

June 3, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003